METTL3 and acute myeloid leukemia: For example, the m6A demethylase METTL3 promotes the occurrence of AML and serves as a potential therapeutic target.[23] Fat mass and obesity‐associated protein (FTO) may act as an oncogene to promote leukemia and inhibit all‐trans retinoic acid‐mediated leukemia cell differentiation.[24] Targeting m6A modification was verified to be significant in potentially refining clinical therapy.[25] In this study, we established an m6Sig score system and confirmed that patients with a lower m6Sig score were characterized by prolonged survival time.